
Opinion|Videos|March 4, 2024
Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer
A medical expert discusses efficacy of approaches such as carboplatin doublets, checkpoint inhibitors, and PARP inhibitors for patients with platinum sensitive and platinum-resistant ovarian cancer.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Oral PCSK9 Inhibitor Enlicitide Matches Injectables in Lowering LDL Cholesterol
2
Improving Patient-Centered Cardiovascular Care for Older Adults
3
Mitigate Treatment Burden in Heart Failure: Martha Gulati, MD
4
Introduction of Work Requirements to Medicaid Enrollment Could Destabilize Health: William Schpero, PhD, MPhil, MPH
5

















































